Regulators of apoptosis as anticancer targets

Hematology/Oncology Clinics of North America

Volumn 16, Issue 5, 2002, Pages 1255-1267

  Tolcher, Anthony W ^a,b  

^a CTRC Institute for Drug Development   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; FLUDARABINE; GENE PRODUCT; IRINOTECAN; MITOMYCIN; MITOXANTRONE; OBLIMERSEN; PACLITAXEL; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTISENSE OLIGODEOXYNUCLEOTIDE; APOPTOSIS REGULATORY PROTEIN; MEMBRANE PROTEIN; NUCLEOTIDE; RECOMBINANT PROTEIN; RETINOIC ACID; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROTEIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; FATIGUE; FEVER; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MICROTUBULE; PRIORITY JOURNAL; REVIEW; SKIN INFLAMMATION; THROMBOCYTOPENIA; TUMOR CELL DESTRUCTION; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG DESIGN; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROTO ONCOGENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CLINICAL TRIALS; DRUG DESIGN; GENES, BCL-2; HUMANS; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; THIONUCLEOTIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRETINOIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036817033     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00046-1     Document Type: Review

References (95)

1. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14; 18) chromosome translocation. Science 1984;226:1097-9.
2. Tsujimoto Y, Ikegaki N, Croce CM. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene 1987;2:3-7.
3. McDonnell TJ, Deane N, Platt FM, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79-88.
4. Thomberry NA. Caspases: A decade of death research. Cell Death Differ 1999;6:1023-7.
5. Thomberry NA, Lazebnik Y. Caspases: Enemies within. Science 1998;281:1312-6.
6. Keane MM, Rubinstein Y, Cuello M, et al. Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat 2000;64:211-9.
7. Sun SY, Yue P, Zhou JY, et al. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun 2001;280:788-97.
8. Hockenbery D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
9. Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-3.
10. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
11. Korsmeyer SJ. Regulators of cell death. Trends Genet 1995;11:101-5.
12. Schendel SL, Montal M, Reed JC. Bcl-2 family proteins as ion-channels. Cell Death Differ 1998;5:372-80.
13. Schendel SL, Xie Z, Montal MO, et al. Channel formation by antiapoptotic protein Bcl-2. Proc Natl Acad Sci U S A 1997;94:5113-8.
14. Minn AJ, Velez P, Schendel SL, et al. Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature 1997;385:353-7.
15. Schlesinger PH, Gross A, Yin XM, et al. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci U S A 1997;94:11357-62.
16. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244-51.
17. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-76.
18. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
19. Cox G, Louise Jones J, Andi A, et al. Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. Lung Cancer 2001;34:417-26.
20. Han H, Landreneau RJ, Santucci TS, et al. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol 2002;33:105-10.
21. Selzer E, Schlagbauer-Wadl H, Okamoto I, et al. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 1998;8:197-203.
22. Jansen B, Schlagbauer-Wadl H, Brown BD, et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232-4.
23. Gleave M, Tolcher A, Miyake H, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:2891-8.
24. Klasa RJ, Bally MB, Ng R, et al. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 2000;6:2492-500.
25. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
26. McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 1997;157:569-74.
27. Bauer JJ, Sesterhenn IA, Mostofi FK, et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996;156:1511-6.
28. Miyake H, Tolcher A, Gleave ME. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res 1999;59: 4030-4.
29. Miyashita T, Reed JC. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992;52:5407-11.
30. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
31. Ohmori T, Podack ER, Nishio K, et al. Apoptosis of lung cancer cells caused by some anticancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 1993;192:30-6.
32. Tolchcr AW, Roth S, Wynne S, et al. G3139 (Genasense) enhances docetaxel antitumor activity and leads to long-term survivors in the androgen-independent prostate cancer xenograph (PC3) model. Clin Cancer Res 2001;7:3680s.
33. Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000;92:34-41.
34. Koty PP, Zhang H, Levitt ML. Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 1999;23:115-27.
35. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin's lymphoma. Lancet 1997;349:1137-41.
36. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with nonHodgkin's lymphoma. J Clin Oncol 2000;18:1812-3.
37. Morris M, Tong W, Osman I, Maslak P, Kelly W, Terry K, et al. A phase I/IIA dose-escalating trial of bcl-2 antisense (G3139) treatment by 14-day continuous intravenous infusion (CI) for patients with androgen-independent prostate cancer or other advanced solid tumor malignancies [abstract]. Proc Annu Meet Am Soc Clin Oncol 18:1243.
38. O'Brien S, Giles F, Rai K, et al. Bcl-2 antisense (Genasense) as monotherapy for refractory chronic lymphocytic leukemia. Blood 2001;98:772a.
39. Pepper C, Thomas A, Hoy T, et al. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 107:611-5.
40. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
41. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A 1995;92:4507-11.
42. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-5.
43. Mooberry SL, Busquets L, Tien G. Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent. Int J Cancer 1997;73:440-8.
44. Smith CD, Zhang X, Mooberry SL, et al. Cryptophycin: A new antimicrotubule agent active against drug-resistant cells. Cancer Res 1994;54:3779-84.
45. Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000;92:34-41.
46. Wang JL, Zhang ZJ, Choksi S, et al. Cell permeable Bcl-2 binding peptides: A chemical approach to apoptosis induction in tumor cells. Cancer Res 2000;60:1498-502.
47. Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 2000;97:7124-9.
48. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000;60:2547-54.
49. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000;6:1655-63.
50. Miyake H, Monia BP, Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 2000;86:855-62.
51. Zellweger T, Miyake H, July LV, et al. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001;3:360-7.
52. Miyake H, Hara S, Zellweger T, et al. Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Mol Urol 2001;5:105-11.
53. Zellweger T, Miyake H, Cooper S, et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 2001;298:934-40.
54. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci U S A 2000;97:3850-5.
55. Strobel T, Swanson L, Korsmeyer S, et al. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A 1996;93:14094-9.
56. Aghajanian C, Soignet S, Dizon D, et al. A phase I trial of the novel proteosome inhibitor PS341 in advanced solid tumor malignancies. Proc Am Soc Clin Oncol 2001;20:85.
57. Papandrcou C, Daliani D, Milikan RE, et al. Phase I study of intravenous (IV) proteosome inhibitor PS-341 in patients with advanced malignancies. Proc Am Soc Clin Oncol 2001; 20:86.
58. Zapata JM, Pawlowski K, Haas E, et al. A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J Biol Chem 2001;276:24242-52.
59. Chinnaiyan AM, Tepper CG, Seldin MF, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996;271: 4961-5.
60. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 2000;97:1754-9.
61. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
62. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8.
63. Meng RD, McDonald 3rd ER, Sheikh MS, et al. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Molecular Therapy: The Journal of the American Society of Gene Therapy 2000;1:130-44.
64. Jiang Y, Woronicz JD, Liu W, Goeddel DV. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 1999;283:543-6.
65. Irie S, Li Y, Kanki H, et al. Identification of two Fas-associated phosphatase-1 (FAP-1) promoters in human cancer cells. DNA Seq 2001;11:519-26.
66. Sato T, Irie S, Kitada S, Reed JC. FAP-1: A protein tyrosine phosphatase that associates with Fas. Science 1995;268:411-5.
67. Landowski TH, Moscinski L, Burke R, et al. CD95 antigen mutations in hematopoietic malignancies. Leuk Lymphoma 2001;42:835-46.
68. Lamy T, Liu JH, Landowski TH, et al. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood 1998;92:4771-7.
69. Landowski TH, Qu N, Buyuksal I, et al. Mutations in the Fas antigen in patients with multiple myelomas. Blood 1997;90:4266-70.
70. Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000;19:5477-86.
71. Munshi A, Pappas G, Honda T, et al. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhabitable by Bcl-2. Oncogene 2001;20:3757-65.
72. Bartke T, Siegmund D, Peters N, et al. p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 2001;20:571-80.
73. Van Antwerp DJ, Martin SJ, Kafri T, et al. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996;274:787-9.
74. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991;285:199-212.
75. Havell EA, Fiers W, North RJ. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 1988;167:1067-85.
76. Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989;143:2894-9.
77. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-9.
78. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 2000;97:1754-9.
79. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
80. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
81. Gibson SB, Oyer R, Spalding AC, et al. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000;20:205-12.
82. Ibrahim SM, Ringel J, Schmidt C, et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001;23:72-9.
83. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000;6:335-46.
84. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-7.
85. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-5.
86. Chuntharapai A, Dodge K, Grimmer K, et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001;166:4891-8.
87. Ichikawa K, Liu W, Zhao L, Wang Z, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7:954-60.
88. Altucci L, Rossin A, Raffelsberger W, et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001;7:680-6.
89. Chi KN, Gleave ME, Klasa R, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001;7:3920-7.
90. de Bono JS, Rowinsky EK, Kuhn J, et al. Phase I pharmacokinetic and pharmacodynamic trial of bcl-2 antisense (Genasense) and docetaxel in hormone-refractory prostate cancer [abstract]. Proc Am Soc Clin Oncol 2001;20:119a.
91. Rudin C, Otterson GA, George CM, et al. A phase I/II trial of Genasense and paclitaxel in chemorefractory small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2001;20:322a.
92. Ochoa L, Kuhn J, Salinas R, et al. A phase I, pharmacokinetic, and biologic correlative study of G3139 and irinotecan (CPT-11) in patients with metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 2001;20:75a.
93. Jansen B, Wacheck V, Heerc-Ress E, et al. Chemosensitisation of malignant melanoma by bcl-2 antisense therapy. Lancet 2000;356:1728-33.
94. Chen HX, Marshall JL, Trocky N, et al. A phase I study of bcl-2 antisense G3139 (Genta) and weekly docetaxel in patients with advanced breast cancer and other solid tumors [abstract]. Proc Am Soc Clin Oncol 2000;19:178a.
95. Marcucci G, Byrd JC, Cataland SR, et al. Significant disease response to Genasense (G3139), a bcl-2 antisense in combination with chemotherapy in refractory or relapsed acute leukemia: A phase I study [abstract]. Clin Cancer Res 2001;7:3681s.